Literature DB >> 28646291

Application of open-access databases to determine functional connectivity between resveratrol-binding protein QR2 and colorectal carcinoma.

Barbara B Doonan1, Evelien Schaafsma2,3, John T Pinto2, Joseph M Wu2, Tze-Chen Hsieh2.   

Abstract

Colorectal cancer (CRC) is a major cause of cancer-associated deaths worldwide. Recently, oral administration of resveratrol (trans-3,5,4'-trihydroxystilbene) has been reported to significantly reduce tumor proliferation in colorectal cancer patients, however, with little specific information on functional connections. The pathogenesis and development of colorectal cancer is a multistep process that can be categorized using three phenotypic pathways, respectively, chromosome instability (CIN), microsatellite instability (MSI), and CpG island methylator (CIMP). Targets of resveratrol, including a high-affinity binding protein, quinone reductase 2 (QR2), have been identified with little information on disease association. We hypothesize that the relationship between resveratrol and different CRC etiologies might be gleaned using publicly available databases. A web-based microarray gene expression data-mining platform, Oncomine, was selected and used to determine whether QR2 may serve as a mechanistic and functional biotarget within the various CRC etiologies. We found that QR2 messenger RNA (mRNA) is overexpressed in CRC characterized by CIN, particularly in cells showing a positive KRAS (Kirsten rat sarcoma viral oncogene homolog) mutation, as well as by the MSI but not the CIMP phenotype. Mining of Oncomine revealed an excellent correlation between QR2 mRNA expression and certain CRC etiologies. Two resveratrol-associated genes, adenomatous polyposis coli (APC) and TP53, found in CRC were further mined, using cBio portal and Colorectal Cancer Atlas which predicted a mechanistic link to exist between resveratrolQR2/TP53CIN. Multiple web-based data mining can provide valuable insights which may lead to hypotheses serving to guide clinical trials and design of therapies for enhanced disease prognosis and patient survival. This approach resembles a BioGPS, a capability for mining web-based databases that can elucidate the potential links between compounds to provide correlations of these interactions with specific diseases.

Entities:  

Keywords:  Colorectal cancer atlas; Colorectal carcinoma (CRC); Oncomine; Quinone reductase 2; Resveratrol; cBio portal

Mesh:

Substances:

Year:  2017        PMID: 28646291     DOI: 10.1007/s11626-017-0174-x

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  18 in total

1.  ONCOMINE: a cancer microarray database and integrated data-mining platform.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

2.  Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.

Authors:  Jochen Gaedcke; Marian Grade; Klaus Jung; Jordi Camps; Peter Jo; Georg Emons; Anastasia Gehoff; Ulrich Sax; Markus Schirmer; Heinz Becker; Tim Beissbarth; Thomas Ried; B Michael Ghadimi
Journal:  Genes Chromosomes Cancer       Date:  2010-11       Impact factor: 5.006

3.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

4.  Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.

Authors:  Ketan R Patel; Victoria A Brown; Donald J L Jones; Robert G Britton; David Hemingway; Andrew S Miller; Kevin P West; Tristan D Booth; Marjorie Perloff; James A Crowell; Dean E Brenner; William P Steward; Andreas J Gescher; Karen Brown
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

5.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Vasudeva Mahavisno; Radhika Varambally; Jianjun Yu; Benjamin B Briggs; Terrence R Barrette; Matthew J Anstet; Colleen Kincead-Beal; Prakash Kulkarni; Sooryanaryana Varambally; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

Review 6.  NAD+ and vitamin B3: from metabolism to therapies.

Authors:  Anthony A Sauve
Journal:  J Pharmacol Exp Ther       Date:  2007-12-28       Impact factor: 4.030

7.  Quantitation of intracellular NAD(P)H can monitor an imbalance of DNA single strand break repair in base excision repair deficient cells in real time.

Authors:  Jun Nakamura; Shoji Asakura; Susan D Hester; Gilbert de Murcia; Keith W Caldecott; James A Swenberg
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

8.  Transcriptome profile of human colorectal adenomas.

Authors:  Jacob Sabates-Bellver; Laurens G Van der Flier; Mariagrazia de Palo; Elisa Cattaneo; Caroline Maake; Hubert Rehrauer; Endre Laczko; Michal A Kurowski; Janusz M Bujnicki; Mirco Menigatti; Judith Luz; Teresa V Ranalli; Vito Gomes; Alfredo Pastorelli; Roberto Faggiani; Marcello Anti; Josef Jiricny; Hans Clevers; Giancarlo Marra
Journal:  Mol Cancer Res       Date:  2007-12       Impact factor: 5.852

9.  Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer.

Authors:  Anthony V Nguyen; Micaela Martinez; Michael J Stamos; Mary P Moyer; Kestutis Planutis; Christopher Hope; Randall F Holcombe
Journal:  Cancer Manag Res       Date:  2009-04-03       Impact factor: 3.989

10.  Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer.

Authors:  Sergio Kaiser; Young-Kyu Park; Jeffrey L Franklin; Richard B Halberg; Ming Yu; Walter J Jessen; Johannes Freudenberg; Xiaodi Chen; Kevin Haigis; Anil G Jegga; Sue Kong; Bhuvaneswari Sakthivel; Huan Xu; Timothy Reichling; Mohammad Azhar; Gregory P Boivin; Reade B Roberts; Anika C Bissahoyo; Fausto Gonzales; Greg C Bloom; Steven Eschrich; Scott L Carter; Jeremy E Aronow; John Kleimeyer; Michael Kleimeyer; Vivek Ramaswamy; Stephen H Settle; Braden Boone; Shawn Levy; Jonathan M Graff; Thomas Doetschman; Joanna Groden; William F Dove; David W Threadgill; Timothy J Yeatman; Robert J Coffey; Bruce J Aronow
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  2 in total

1.  PANoptosis-based molecular clustering and prognostic signature predicts patient survival and immune landscape in colon cancer.

Authors:  Xu Wang; Rui Sun; Shixin Chan; Lei Meng; Yuanmin Xu; Xiaomin Zuo; Zhenglin Wang; Xianyu Hu; Qijun Han; Longfei Dai; Tao Bai; Zhen Yu; Ming Wang; Wenqi Yang; Huabing Zhang; Wei Chen
Journal:  Front Genet       Date:  2022-09-14       Impact factor: 4.772

2.  Development of prognosis model for colon cancer based on autophagy-related genes.

Authors:  Xu Wang; Yuanmin Xu; Ting Li; Bo Chen; Wenqi Yang
Journal:  World J Surg Oncol       Date:  2020-10-30       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.